A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Public ClinicalTrials.gov record NCT00074854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy (Paclitaxel And Carboplatin) Vs. Chemotherapy Alone For The Treatment Of Advanced Stage Non-Small Cell Lung Cancer.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage non-small cell lung cancer.
Study identification
- NCT ID
- NCT00074854
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 87 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2002
- Primary completion
- Not listed
- Completion
- Feb 28, 2005
- Last update posted
- Nov 8, 2006
2002 – 2005
United States locations
- U.S. sites
- 20
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Greenbrae | California | 94904 | — |
| Pfizer Investigational Site | San Mateo | California | 94402 | — |
| Pfizer Investigational Site | San Pablo | California | 94806 | — |
| Pfizer Investigational Site | Tampa | Florida | 33612-9497 | — |
| Pfizer Investigational Site | Covington | Louisiana | 70433 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70002 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70006 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70115 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Stony Brook | New York | 11794 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
| Pfizer Investigational Site | Gallatin | Tennessee | 37066 | — |
| Pfizer Investigational Site | Hermitage | Tennessee | 37076 | — |
| Pfizer Investigational Site | Lebanon | Tennessee | 37087 | — |
| Pfizer Investigational Site | Murfreesboro | Tennessee | 37130 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37205 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37207 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37211 | — |
| Pfizer Investigational Site | Smyrna | Tennessee | 37167 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00074854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2006 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00074854 live on ClinicalTrials.gov.